Our present study showed that TET2, ASXL1 and DNMT3A mutations were common in MDS patients (with mutation ratios 20.3%, 10.7% and 10.7%, respectively) and they all had co-mutations, but they were not found to be correlated with MDS prognosis. Here, ASXL1 is linked to myelodysplastic syndrome.